Compare Organon & Co. Common Stock (OGN) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Paychex, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Paychex, Inc. trades at $109.39 (market cap $37.82B). The key difference: Paychex, Inc. is far larger — about 10.4× Organon & Co. Common Stock's market cap, and Paychex, Inc. pays the higher dividend (4.48%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Paychex, Inc. for 56 Days on average.
| OGN | PAYX | |
|---|---|---|
Market Cap | $3.62B | $37.82B |
Volume | 2,892,999 | 2,018,238 |
Sector | Health | Industrials |
52-Week High | $13.81 | $127.54 |
52-Week Low | $5.70 | $85.57 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $11.04B | $41.51B |
Dividend Yield | 0.58% | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Paychex (PAYX) trades at $108.37, up 3.56% today, with mixed technical signals showing bullish overall momentum but bearish moving averages. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.34 beating $1.32 estimates, and robust profitability metrics including 27.35% net income margin and 47.06% ROE. Recent news highlights dividend safety concerns despite the company's 5-star rating on Newsweek's America's Greatest Companies 2026 list.
Outlook remains cautiously optimistic with analyst consensus target of $111 suggesting modest upside, though high valuation multiples (P/E 21.08, P/S 5.77) and competitive pressures in payroll services present risks. The stock offers income potential with recent $1.19 dividend, but investors should monitor PEO segment performance and labor market trends affecting small business clients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
